Simultaneous pancreas-kidney transplantation: Initial experience of a center in Japan by Ono Shinichiro et al.
Contents lists available at ScienceDirect
Transplantation Reports
journal homepage: www.elsevier.com/locate/tpr
Simultaneous pancreas-kidney transplantation: Initial experience of a center
in Japan
Shinichiro Onoa, Tomohiko Adachia, Masaaki Hidakaa, Koji Natsudaa, Yasuhiro Maruyaa,
Riccardo Pravisania, Yasushi Mochizukib, Motohiro Sekinoc, Kengo Kanetakaa,
Mitsuhisa Takatsukia, Susumu Eguchia,⁎
a Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Japan 852-8501
bDepartment of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
c Division of Intensive Care, Nagasaki University Hospital, Nagasaki, Japan






A B S T R A C T
Background: Simultaneous pancreas-kidney transplantation (SPK) is an established therapy for diabetes mellitus
(DM) patients with associated end stage renal disease. We report the initial results of SPK in our institution after
qualification as transplantation program.
Patients and methods: Between September 2017 and July 2018, we performed 3 SPK in type 1 diabetic patients
with end-stage renal disease. All grafts were procured from brain-dead marginal donors according Pittsburg
criteria.
Results: The recipients were 2 men and 1 woman with a mean age of 43 ± 5.4 years. Mean time from DM
diagnosis and time on dialysis were 25.7 ± 3.9 years and 19.7 ± 9.1 months. The mean age and HbA1C value
of donor were 56.7 ± 0.5 years and 5.67 ± 0.05%. The pancreatic grafts were transplanted intraperitoneally in
the right iliac fossa. Two patients required a relaparotomy due to arterial anastomotic hemorrhage and two
patients developed acute cellular rejection. With a median follow-up of 13 (6–15) months, patient's and graft's
survival rate were 100%. All patients showed HbA1C within normal range, but oral glucose tolerance test
showed DM pattern in two patients at 3 months after transplantation.
Conclusions: In our initial experience with SPK, mid-term grafts and patient survival appear comparable to the
results reported in literature. Despite the limited availability of donors and the use of grafts from marginal
donors, a quality pancreas transplantation program can be established even in a small-volume centers.
Nonetheless further improvement in surgical techniques and meticulous management appear mandatory.
1. Introduction
Simultaneous pancreas-kidney transplantation (SPK) is an estab-
lished treatment for type 1 diabetic patients with end-stage renal dis-
ease [1]. The outcome of SPK has improved thanks to significant ad-
vances in surgical technique [2], preservation methods [3,4] and
immunosuppression regimens [4]. Nonetheless pancreas graft is still
associated with a significant burden of early severe complications, in-
cluding thrombosis (prevalence 10–20%), graft duodenal perforation
(%) and acute cellular rejection (20% within the first year) which are
associated with high risk of graft loss (REF).
In Japan, the annual number of brain death donors has dramatically
increased thanks to the revision of the law on organ Transplantation in
2010. However, the rate of organ donation is currently about 70–80
cases per year, which is far less than in other countries. Due to such
severe shortage of donations, the annual number of pancreas trans-
plantation in Japan is around 35 cases compared to over 200 candidates
on transplant waiting list. In the United States, more than 65% of
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waiting patients is transplanted within 1 year [5], while in Japan, the
median waiting time for pancreas transplantation is around three and
half year and a nearly 25% of patients have been waiting more than 5
years [6].
Under such circumstances, it is expected that the development of a
new pancreas transplantation program in a small volume center may
face several difficulties.
Our Institution has performed 285 cases of liver transplantation and
258 case of kidney transplantation, since the brief case respectively in
1997 and 1965 until now. Between September 2017 and July 2018, we
performed 3 cases of SPK in type 1 diabetic patients with end-stage
renal disease.
On October 2016 Our Institution received the certification as 18th
facility for pancreas transplantation in Japan and between September
2017 and July 2018, we performed 3 cases of SPK. The aim of the
present study was to report the result of our initial experience
2. Patients and methods
Clinical and demographic characteristics of recipients and donors as
well as data about transplant surgical procedure and postoperative
course were retrospectively reviewed after approval by the ethical
committee of Nagasaki university hospital (#15052506).
Selection criteria for SPK indication were DM type 1 associated with
end-stage renal disease in dialysis therapy.
All grafts were procured from brain-dead donors and were pre-
served with University of Wisconsin solution.
Pancreas was implanted intraperitoneally in the right iliac fossa
trough a modified hockeystick incision. Graft artery and portal vein
were respectively anastomosed to the recipient's external iliac artery
and vein. A Carrel patch and a Y-graft were employed in 2 and 1 case
respectively. After bringing a jejunal limb, graft exocrine drainage was
provided by anastomosis of the duodenum graft to a Roux-en-Y jejunal
limb in a side-to-side fashion by two-layer continuous running suture.
Kidney was implanted retroperitoneally in the left iliac fossa, with
anastomosis of graft renal artery and vein to recipient's external iliac
artery and vein respectively. Ureter was anastomosed to the urinary
bladder using Lich-Gregoir standard technique.
Immunosuppression protocol was based on induction with basilix-
imab and maintenance with calcineurin inhibitor (CNI), mycophenolate
mofetil (MMF) and steroid.
Thromboprofilax protocol was based on intravenous heparin infu-
sion. It was started during transplantation at kidney graft reperfusion
and was maintained until POD 10. Thereafter it was switched to low
dose aspirin. Target range of activated partial thromboplastin time
(APTT) during heparin infusion was between 45 and 60 s. For anti-
microbial perioperative prophylaxis, third generation cephalosporin
and micafungin sodium 100mg were given for 3 and 7 days respec-
tively. CMV prophylaxis was not routinely used.
After hospital discharge all the patients were followed up clinically
and monitored for grafts function by physical examination and la-
boratory test for fasting glucose, HbA1C, C-peptide, amylase, lipase,
creatinine and anti-CMV pp65 antibody. In additionally oral glucose
tolerance test (OGTT) was performed periodically.
3. Results
The recipients were 2 men and 1 woman, with a mean age of
43 ± 5.4 years, HbA1C value of 8.1 ± 1.1%, the duration of DM of
25.7 ± 3.9 years and time on dialysis of 19.7 ± 9.1 months.
According to the Minnesota criteria [7] and Pittsburg criteria [8], all
donors were classified as marginal donors. The mean donor age was
56.7 ± 0.5 years, body mass index 22.9 ± 1.3 kg/m2. In two donors,
the cause of death was cerebrovascular disease while for all of the
donors a cardio-pulmonary arrest was reported. All of donors used at
least two types of vasopressors. The mean HbA1C and serum creatinine
value were 5.67 ± 0.05% and 0.62 ± 0.11mg/dl respectively. The
mean number of HLA mismatch was 3.7 ± 1.2. The characteristics of
donors and recipients were summarized in Table 1.
The mean total ischemia times was 597 ± 110 min for the renal
grafts and 841 ± 95 min for the pancreatic grafts. The implantation
time for pancreas and kidney were 316 ± 13 and 258 ± 27 min re-
spectively. Mean blood loss was 1032 ± 246 gr.
The postoperative course of each patient was summarized in
Table 2. Three episodes of acute bleeding requiring relaparotomy oc-
curred in 2 patients within POD 1. No hemodynamic instability was
associated. At surgical exploration the source of bleeding was the
pancreas arterial anastomosis in 2 cases and kidney arterial anastomosis
in 1 case. Thereafter, one patient developed a peripancreatic abscess
without any signs of pancreatic leak or duodenal perforation, which
was treated with surgical toilette.
No cases of pancreas graft trombosis, ileus, delayed graft function of
the kidney, or urologic complications were recorded.
Two patients developed an episode of acute cellular rejection (ACR)
at POD 30 and 49 respectively. In one patient, rejection affected only
the kidney while in the other it was combined pancreas-kidney. Both
patients were treated with steroid pulse and r-ATG with normalization
of laboratory tests. However, in the recipient who developed a com-
bined kidney-pancreas ACR, a CMV infection occurred during r-ATG
therapy. Therefore, intravenous ganciclovir and intravenous gamma-
globulin were administered and the immunosuppression was tapered.
No cases of antibody-mediated rejection were recorded.
The mean HbA1C and serum creatinine level at 1, 3, 6, 12 months
after transplantation were 5.1 ± 0.2%, 5.2 ± 0.2%, 5.5 ± 0.1% and
5.5 ± 0.1% and 1.3 ± 0.2mg/dl, 1.4 ± 0.2 mg/dl, 1.4 ± 0.2mg/dl
and 1.6 ± 0mg/dl.
Despite of a normal HbA1c, two patients showed DM pattern at
OGTT at 3 months after transplantation. The mean HOMA-IR at 3 and
12 months after transplantation were 0.98 ± 0.35 and 0.87 ± 0.27.
The mean HOMA-β at 3 and 12 months after transplantation were
36.1 ± 10.9 and 48.3 ± 20. Trends of HOMA-IR and HOMA-β were
summarized in Fig. 1A and B. In the glucagon stimulation test, all pa-
tients showed ΔCPR ≥ 2 at any time. With a median follow-up of 13
[6–15] months, patient's and all graft's survival rate were 100%.
4. Discussion
Due to the significant shortage of deceased donor in Japan, up to
63% of pancreas grafts are currently obtained from marginal donors
according Pittsburg criteria [8,9]. Indeed, all the donors in the present
Table 1
Characteristics of donor and recipient (n=3).
Characteristics value
Recipient
Age (yr) 43 ± 5.4
Gender (male, female) 2:1
HbA1C 8.1 ± 1.1
Duration of diabetes (yr) 25.7 ± 3.9
Duration of dialysis (mo) 19.7 ± 9.1
Donor
Age (yr) 56.7 ± 0.5
Gender (male, female) 1:2
Body mass index (kg/m2) 22.9 ± 1.3
Cause of death
Cerebrovascular disease 2 (66.6%)
Hypoxic brain damage 1 (33.3%)
Pre-procurement HbA1C (%) 5.67 ± 0.05
Pre-procurement creatinine (mg/dl) 0.62 ± 0.11
Marginal donor
Minnesota criteria 3 (100%)
Pittsburg criteria 3 (100%)
HLA mismatch 3.7 ± 1.2
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clinical series were classified as marginal. Such characteristics may
potentially compromise the outcome of SPK [6,8]. In our series, two
patients showed a negative trend of HOMA-β during the follow-up
which may be due to a low graft quality from marginal donors. These
patients may require dipeptidyl peptidase-4 inhibitors in the future for
beta cell protection and insulin secretion promotion. Furthermore, it
has been reported that grafts from marginal donors are associated with
an increased risk of pancreas graft thrombosis and graft loss [10,11].
Other identified risk factors for graft thrombosis comprise vascular in-
jury during organ procurement, quality of preservation and reperfusion,
surgical technique [12], decrease in flow rate of drainage vein [13] and
hyper coagulated state after surgery [14]. With the aim to minimize the
risk of graft thrombosis, the selected thromboprofilax protocol at our
Institution was based on intraoperative start of intravenous heparin
infusion for the first 10 postoperative days, as modified protocol of
previous report [15]. However, this management was surely associated
with a higher hemorrhagic risk which was the probable cause of the 3
cases of early postoperative hemorrhage requiring relaparotomy in the
present series. Nonetheless, no hemodynamic instability was asso-
ciated, the prompt surgical bleeding control resulted effective and at a
mean follow up time of 13 months all the grafts are well functioning.
The other main concern of the present clinical series was ACR. The
overall prevalence of kidney ACR in our institution was 8.9% which
appears to be in line with the data as reported [16]. In our series, all
patients were inducted by basiliximab and in two of three patients
developed ACR, such results may be clinically significant and require
any immunosuppresive protocol change for the moment. Compared
basiliximab and r-ATG, r-ATG had an effect to decrease the acute cel-
lular rejection in the first year after SPK with similar side effects as an
induction therapy [17]. Besides r-ATG is not covered by health in-
surance in Japan at the moment. Anyway, new cases of SPK will surely
provide additional data. Nonetheless ACR of pancreas graft is asso-
ciated with increased risk for not only acute but also chronic graft loss.
In the single case of ACR of the present series, the graft recovered
completely after administration steroid pulse and r-ATG, but longer
follow-up will be needed for evaluation of long-term outcome.
In our initial experience with SPK, mid-term grafts and patient
survival appear comparable to the results reported in literature. Despite
the limited availability of donors and the use of grafts from marginal
donors, a quality pancreas transplantation program can be established
even in a small-volume centers. Nonetheless further improvement in
surgical techniques and meticulous management appear mandatory.
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Table 2
Postoperative course of the recipients.
Total Patient 1 Patient 2 Patient 3
Surgical complications
Bleeding 2 (66.7%) Pancreas arterial anastomosis
POD 1








Pancreas graft thrombosis 0 None None None
Duodenal perforation 0 None None None
Graft rejection
Pancreas ACR 1 (33.3%) None POD 49
Treated with steroid pulse + r-ATG therapy
None
Kidney ACR 2 (66.7%) POD 30
Treated with steroid pulse and r-ATG therapy
POD 49
Treated with steroid pulse + r-ATG therapy
None














Fig. 1. A: All patients showed normal value of HOMA-IR at 3 and 12 months
after transplantation. B: Two patients showed low value of HOMA-β at 3
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